Pharma Major Lupin Reports 87.7% Jump in Quarterly PAT

Lupin Ltd on Thursday reported an 87.7 per cent increase in consolidated profit after tax for the fourth quarter ended March 31, 2026, driven largely by strong performance in the United States market.

According to a regulatory filing, the company’s consolidated profit after tax stood at Rs 1,468.7 crore during the January-March quarter, compared to Rs 782.4 crore recorded in the same quarter of the previous financial year.

The pharmaceutical major also reported substantial growth in revenue during the quarter. Consolidated sales rose 32.9 per cent to Rs 7,391.9 crore, up from Rs 5,562.2 crore in the corresponding period last year.

The strong quarterly performance reflects healthy demand for Lupin’s products in international markets, particularly in the US, which remains one of the company’s key revenue contributors.

Lupin Ltd is among India’s leading pharmaceutical firms with operations spanning branded and generic medicines, biotechnology products and active pharmaceutical ingredients across global markets.

Industry experts believe the company’s strong growth highlights the continued momentum in the Indian pharmaceutical sector, especially among firms with a strong presence in regulated overseas markets such as the United States.

The results are expected to boost investor confidence as global pharmaceutical demand and export opportunities continue to support revenue expansion for Indian drug manufacturers.